nder pressure to appease investors, Sanofi (SNY) has twice in the past week agreed to pay hefty amounts of money to buy a pair of companies that specialize in treating blood disorders. In doing so, the drug maker is scrambling to remake itself as its key diabetes franchise struggles under pricing pressure.

The latest deal involves paying more than $4.8 billion for Ablynx (ABLYF), which is researching rare blood disorders and developing novel drugs based on so-called nanobodies that are found in the immune systems of llamas and alpacas. Just last week, the drug maker paid agreed to pay $11.6 billion for Bioverativ (BIVV) — and a pair of hemophilia treatments — that was spun off by Biogen (BIIB).

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.